Clinical trials: Thymus Neoplasms
Thymoma and Thymic Carcinoma, Pleural Metastasis
Phase II Trial of Hypofractionated Radiotherapy Guided by Optical Surface Imaging and Fan-beam CT for Thymoma With Pleural Metastasis
This trial plans to conduct a prospective, randomized controlled phase II clinical study to explore the efficacy and safety of hypofractionated radiotherapy guided by optical surface imaging combined with FBCT in patients with…
- Trial name
- NCT07879417
- Testing
- hypofractionated radiotherapy guided by optical surface imaging and FBCT, hypofractionated radiotherapy guided by CBCT
- Volunteers
- 234 people
- Sponsor
- Sun Yat-sen University
Anal Carcinoma, Bladder Carcinoma
Determining the Biodistribution of an Imaging Tracer (68Ga-FAPi-46) in Patients With Solid Tumors or Hematologic Cancers
This phase I trial is evaluating a new imaging tracer (68Ga-FAPi-46) with positron emission tomography (PET)/computed tomography (CT) to determine where and to which degree the tracer (68Ga-FAPi-46) accumulates in normal and…
- Conditions
- Anal Carcinoma, Bladder Carcinoma, Breast Carcinoma, Cervical Carcinoma
- Trial name
- NCT07118176
- Testing
- Computed Tomography, Fludeoxyglucose F-18, Gallium Ga 68 FAPi-46
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Neuroendocrine Tumors, Lung Neuroendocrine Neoplasm
Efficacy and Safety of Radiotherapy Compared to Everolimus in Somatostatin Receptor Positive Neuroendocrine Tumors of the Lung and Thymus.
LEVEL trial aims to demonstrate the higher efficacy of 177Lu-edotreotide over everolimus in patients with well to moderately differentiated neuroendocrine tumors of the lung and thymus who require systemic therapy.
- Conditions
- Neuroendocrine Tumors, Lung Neuroendocrine Neoplasm, Thymus Neoplasms
- Trial name
- LEVEL (NCT05918302)
- Testing
- 177Lu-edotreotide, Everolimus
- Where
- 27 sites in Belgium, France and 2 more
- Volunteers
- 170 people
- Sponsor
- Grupo Espanol de Tumores Neuroendocrinos
Thymoma
Single Cell Sequencing Analysis of Thymoma
The purpose of this study is to understand how genetics play a role in thymoma. Intratumoral heterogeneity is among the greatest challenges in precision cancer therapy.
- Trial name
- NCT04162691
- Testing
- Tissue
- Where
- China
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Zhejiang Cancer Hospital
Type B3 Thymoma, Thymic Carcinoma
Trial of Sunitinib in Patients With Type B3 Thymoma or Thymic Carcinoma in Second and Further Lines (Style Trial)
Study to investigate response to sunitinib in patients with thymic epithelial tumours who had progressive disease after at least one previous regimen of platinum-based chemotherapy.
- Trial name
- Style (NCT03449173)
- Testing
- Sunitinib
- Where
- Italy
- Volunteers
- 56 people
- Sponsor
- Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Locally Advanced Stage III or IV Thymic Cancer
Neoadjuvant Chemotherapy for Locally Advanced Thymic Cancer
We try to evaluate whether neoadjuvant docetaxel plus cisplatin can increase the complete resection rate in advanced thymic carcinoma.
- Trial name
- NCT01312324
- Testing
- neoadjuvant docetaxel/cisplatin
- Where
- South Korea
- Volunteers
- 27 people
- Sponsor
- Samsung Medical Center
Thymoma, Thymic Carcinoma
Phase II Study of Alimta (Pemetrexed) Treatment of Advanced Thymoma and Thymic Carcinoma
To study the efficacy of Alimta as a single agent in thymic cancers
- Trial name
- NCT00198133
- Testing
- Premetrexed (Alimta)
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- Patrick Joseph Loehrer Sr.
Thoracic Neoplasms, Lung Neoplasms
Thoracic OncoGeriatric Assessment (TOGA) Trials
Our goal is to develop a reliable, physician and patient-friendly, pre-operative Thoracic Onco-Geriatric Assessment (TOGA) to predict surgical risk in geriatric oncology patients with thoracic neoplasms of the lung, esophagus…
- Conditions
- Thoracic Neoplasms, Lung Neoplasms, Esophagus Neoplasms, Pleural Neoplasms
- Trial name
- TOGA (NCT00591981)
- Testing
- TOGA Tools
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- University of Wisconsin, Madison
B2 Thymoma, Thymic Carcinoma
Target-Selected CAR-NK Cells (CD30, CD5, or Mesothelin) for Relapsed/Refractory B2 Thymoma or Thymic Carcinoma
This Phase 1/2 study evaluates the safety, tolerability, and preliminary efficacy of target-selected CAR-natural killer (CAR-NK) cells in adults with relapsed or refractory B2 thymoma or thymic carcinoma.
- Trial name
- SELECT-NK-THYM (NCT07598955)
- Testing
- Cyclophosphamide, Fludarabine, EB-CAR30-NK
- Where
- China
- Volunteers
- 36 people
- Sponsor
- Beijing Biotech
Thymic Carcinoma
Sacituzumab Tirumotecan in Participants With Locally Advanced or Metastatic Thymic Carcinoma
The goal of this clinical trial is to learn if drug Sac-TMT works to treat Thymic Carcinoma. It will also learn about the safety of Sac-TMT.
- Trial name
- NCT07324629
- Testing
- Sacituzumab tirumotecan
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Prostate Cancer
Effect of Androgen Blockade Therapy on Thymus Function in Older Patients Who Have Undergone Radical Prostatectomy for Localized Prostate Cancer
RATIONALE: Studying changes in thymus function in patients who have been undergoing androgen blockade therapy for prostate cancer may help doctors learn more about how well patients will respond to treatment, may help in planning…
- Trial name
- NCT00379119
- Testing
- diagnostic laboratory biomarker analysis, flow cytometry, physiologic testing
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- University of California, San Francisco
Thymic Carcinoma, Thymoma
Ramucirumab and Carbo-Paclitaxel for Untreated Thymic Carcinoma / B3 Thymoma With Carcinoma (RELEVENT)
This is a multicentric study. All patients with TET (thymic epithelial tumors) of any histological type will participate in the study.
- Trial name
- RELEVENT (NCT03921671)
- Testing
- Ramucirumab
- Where
- Italy
- Volunteers
- 60 people
- Sponsor
- Claudia Proto
Thymoma
Abscopal Effect of Radiotherapy in Combination With rhGM-CSF for Advanced Thymic Epithelial Tumours
The purpose of this study is to determine whether radiotherapy (RT) combined with recombined human granulocyte-macrophage colony stimulating factor(rhGM-CSF) is safe, effective in the treatment of patients with advanced thymic…
- Trial name
- NCT05407649
- Testing
- Radiotherapy Combined with GM-CSF
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Shanghai Cancer Hospital, China
Thymic Carcinoma, Thymus Neoplasms
Pembrolizumab and Epacadostat in Patients With Thymic Carcinoma
This is a non-randomized clinical trial in patients with thymic carcinomas who failed prior systemic therapy. All subjects will receive pembrolizumab and epacadostat treatment in three week cycles until unacceptable toxicity…
- Conditions
- Thymic Carcinoma, Thymus Neoplasms, Thymus Cancer
- Trial name
- NCT02364076
- Testing
- Pembrolizumab, Epacadostat
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- Georgetown University
Thymoma, Mediastinal Tumor
Clinical Investigation of the da Vinci Surgical System
This prospective, multicenter, single-arm study is being conducted to confirm safety, effectiveness, and usability of da Vinci Surgical System in performing robotic-assisted surgical procedures.
- Conditions
- Thymoma, Mediastinal Tumor, Gynecologic Disease, Gynecologic Cancer
- Trial name
- NCT05682742
- Testing
- Robotic-assisted Surgery
- Where
- 4 sites in United States
- Volunteers
- 53 people
- Sponsor
- Intuitive Surgical
Thymic Epithelial Tumor, Recurrent Thymoma
PT-112 in Subjects With Thymoma and Thymic Carcinoma
Background: There are no approved drugs to treat recurrent thymoma and thymic carcinoma. New therapies are needed for people with these cancers. Researchers want to see if the drug PT-112 can help. PT-112 kills cancer cells.
- Conditions
- Thymic Epithelial Tumor, Recurrent Thymoma, Thymic Cancer
- Trial name
- NCT05104736
- Testing
- PT-112
- Where
- United States
- Volunteers
- 53 people
- Sponsor
- National Cancer Institute (NCI)
Astrocytoma, Brain Cancer
Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of QBS10072S
This is a multi-center, open-label, dose escalation study to determine the safety, tolerability, pharmacokinetics, pharmacodynamics, and maximum tolerated dose (MTD) of QBS10072S in patients with advanced or metastatic cancers…
- Conditions
- Astrocytoma, Brain Cancer, Brain Metastases, Bladder Cancer
- Trial name
- NCT04430842
- Testing
- QBS10072S
- Where
- 2 sites in Australia
- Volunteers
- 15 people
- Sponsor
- Quadriga Biosciences, Inc.
Life Threatening Diseases
Phase II Study of Imatinib Mesylate in Patients With Life Threatening Malignant Rare Diseases
Exploratory study to examine the effect(s) of Imatinib mesylate treatment on life threatening rare diseases with known associations to one or more Imatinib mesylate -sensitive tyrosine kinases, and to identify the contribution of…
- Trial name
- NCT00154388
- Testing
- Imatinib mesylate
- Volunteers
- 185 people
- Sponsor
- Novartis Pharmaceuticals
Thymoma and Thymic Carcinoma
Chemoradiotherapy for Limited Advanced Unresectable Thymic Epithelial Tumors
This study is designed to evaluate the feasibility and safety of concurrent chemoradiotherapy for limited advanced unresectable thymoma or thymic carcinoma.
- Trial name
- NCT02636556
- Testing
- concurrent chemoradiation
- Where
- China
- Volunteers
- 56 people
- Sponsor
- Fudan University
Thymic Carcinoma
Pembrolizumab and Sunitinib Malate in Treating Participants With Refractory Metastatic or Unresectable Thymic Cancer
This phase II trial studies how well pembrolizumab and sunitinib malate work in treating participants with thymic cancer that has spread to other places in the body or cannot be removed by surgery and does not respond to…
- Trial name
- NCT03463460
- Testing
- Laboratory Biomarker Analysis, Pembrolizumab, Sunitinib Malate
- Where
- 3 sites in United States
- Volunteers
- 9 people
- Sponsor
- Dwight Owen